Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Edwards Lifesciences product launches

This article was originally published in The Gray Sheet

Executive Summary

Firm will add self-expanding non-coronary stents in the coming months to the LifeStent product line. On Sept. 30, Edwards announced the release of two balloon-expandable stents, theSDS Biliary System and SDS Peripheral system, both 510(k)-cleared earlier this year (1"The Gray Sheet" Sept. 15, 2003, p. 10)...

You may also be interested in...

Bear Stearns 2003 Healthcare Conference In Brief

Edwards Lifesciences R&D: LifeStent biliary stent will launch within weeks, heralding series of peripheral stent offerings over next six months, Edwards VP-Technology Stuart Foster says at Bear Stearns annual healthcare conference in New York Sept. 8. Edwards is assembling a dedicated sales team to support the line, developed through agreements with Orbus and Syntheon (1"The Gray Sheet" Nov. 18, 2002, p. 23). Foster also notes that Perimount Magna should obtain FDA clearance by year-end. To be priced at a premium to Perimount, the next-gen mitral valve will feature improved hemodynamics and durability. Regarding catheter-based valve repair, Edwards expects the first clinical implants of its "edge-to-edge" procedure to begin in 2004. In 2005, Edwards anticipates clinical trials of a catheter-based replacement system for aortic valves. Also in Edwards' valve repair pipeline is the Thermafix anti-calcification method, which could be approved by FDA later this year. Edwards is preparing a modular PMA submission for the Lifepath AAA endograft, based on Phase II pivotal study data, to be presented at the VEITHsymposium in New York Nov. 21-24...

Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

World-First Nod For Yuhan's Lung Cancer Drug, In Korea

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts